Trial site
CHU de Quebec - Hôpital de l' Enfant Jésus
Québec, G1J 1Z4, CanadaNot linked to an institution yet
- 11running trials
- 6closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 15 trials
- Phase 2/34 trials
- Status
- Active, not recruiting8 trials
- Completed4 trials
- Recruiting3 trials
- Terminated2 trials
- Lead sponsor
- Amgen5 trials
- Washington University School of Medicine4 trials
- Bayer2 trials
- Biogen2 trials
- Hoffmann-La Roche2 trials
- and 2 more
Running trials
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957· Phase 1· Amgen· Source
Recruiting
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498· Phase 2/3· Washington University School of Medicine· Source
Contact: Robert LaForce (principal investigator)
Recruiting
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT05552157· Phase 2/3· Washington University School of Medicine· Source
Contact: Robert LaForce (principal investigator)
Active, not recruiting
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036· Phase 3· Amgen· Source
Active, not recruiting
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354· Phase 1· Amgen· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT05361395· Phase 1· Amgen· Source
Active, not recruiting
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
NCT05269394· Phase 2/3· Washington University School of Medicine· Source
Active, not recruiting
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883· Phase 1· Amgen· Source
Active, not recruiting
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005· Phase 2/3· Washington University School of Medicine· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error